A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
HealthWatch
FDA blocked melanoma drug as confusion reigned under Makary
By Arthur Allen
May 15, 2026 / 5:00 AM EDT / KFF Health News
Add CBS News on Google
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary - KFF Health News
Regeneron immunotherapy combo comes up short in melanoma trial
Regulatory round-up: A month of key FDA approvals for cancer drugs - Pharmaceutical Technology
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
Astellas treatment offers new hope to a devastated rare disease community
A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout
Replimune will resubmit advanced melanoma drug RP1 to the FDA after two rejections, following the ouster of Commissioner Marty…
The FDA rejected vusolimogene oderparepvec twice under former Commissioner Marty Makary, who stepped down earlier this month
